Voyager Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VYGR research report →
Range $8 – $18
Price Chart
About the company
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease.
- CEO
- Alfred W. Sandrock Jr.
- IPO
- 2015
- Employees
- 141
- HQ
- Lexington, MA, US
Get TickerSpark's AI analysis on VYGR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $95.21M
- P/E
- -0.96
- PEG
- -0.04
- P/S
- 4.14
- P/B
- 0.76
- EV/EBITDA
- -0.85
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -450.12%
- Net Margin
- -416.32%
- ROE
- -63.42%
- ROIC
- -67.83%
Latest fiscal year · YoY change
- Revenue
- $40.37M-49.5%
- Gross Profit
- $-91,900,000-214.9%
- Op Income
- $-131,844,000
- Net Income
- $-119,721,000-84.2%
- EPS
- $-2.04-80.5%
- OCF Growth
- -765.2%
- FCF Growth
- -617.2%
- 52W High
- $5.48
- 52W Low
- $1.48
- 50D MA
- $2.24
- 200D MA
- $3.31
- Beta
- 1.20
- RSI (14)
- 36
- Avg Volume
- 766.88K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Voyager ended 2024 with $332 million in cash and continued advancing its tau-focused pipeline, while moving one SOD1 program back to research after payload issues.· March 11, 2025
- Cash was $332 million at year-end 2024, and management said partnerships remain a major non-dilutive funding source.
- VY1706 tau silencing advanced into IND-enabling studies, with 50% to 73% tau mRNA knockdown seen in three-month non-human primate studies.
- VY7523 anti-tau antibody had a clean SAD readout: no serious adverse events, dose-proportional PK, and a 0.3% CSF-to-serum ratio.
- The SOD1 silencing program moved back to research because the payload did not meet the target profile and needs a new payload.
- Management said the cash runway guidance to mid-2027 excludes potential milestone upside from partnered programs.
Voyager did not provide revenue or EPS on the call. It reported $332 million in cash at the end of 2024, and management highlighted $8.2 billion in potential future milestone payments across partnerships, including $2.9 billion of developmental milestones. For VY1706, the company said three-month non-human primate studies showed 50% to 73% tau mRNA knockdown broadly across the brain, and the program is advancing toward an IND in 2026. For VY7523, management reported no serious adverse events in the SAD study, dose-proportional pharmacokinetics, and a CSF-to-serum ratio of 0.3%. For the SOD1 program, management said the payload did not meet the target profile and the program moved back to research. Forward-looking guidance: management reiterated cash runway guidance into mid-2027, with partnership milestones as additional upside, and expects VY7523 initial tau PET data in the second half of 2026.
Al Sandrock framed Voyager as a multimodality neuro-therapeutics company with four wholly owned and 13 partnered programs, emphasizing tau as the company’s main scientific focus. He stressed that both the tau antibody and tau silencing approaches could matter, and said Voyager intends to make data-driven decisions as more internal and external readouts emerge. His tone was optimistic but measured, with repeated emphasis on partnerships, capital efficiency, and the view that IV delivery and CNS shuttle technologies can be differentiated.
Nathan Jorgensen focused on liquidity and external funding sources, saying Voyager ended 2024 with $332 million in cash and that partnership economics remain important. He cited $2.9 billion of developmental milestones and more than $8 billion when broader biobucks are included, and said those milestones are not included in the mid-2027 cash runway guidance. He also said the company would be thoughtful about any transaction that shortens runway and would only do so for compelling near-term clinical assets or attractive business development opportunities.
Analysts pressed on what upcoming tau readouts could mean for Voyager’s programs, especially ADPD, Merck, J&J, and Biogen-related data. Management said it will be looking for exposure-response, tau PET, subgroup effects such as APOE status, and whether slowing tau spread translates into clinically meaningful benefit. On the antibody side, Voyager said the SAD results support moving into a higher-dose MAD study, and on the silencing side it said the current plan is to use the NHP knockdown data to support an IND in 2026 if GLP tox is clean and a therapeutic window is preserved. Questions also focused on ALPL versus TfR shuttles, where management argued ALPL may offer safety and distribution advantages but said more comparative data are still coming.
The call reinforced that Voyager has multiple shots on goal in tau, with both an antibody and a silencing program advancing. Management believes the NHP tau knockdown is already in the target range and that the antibody showed encouraging early safety and PK, while partnerships provide a large pool of potential non-dilutive funding. The company also sounded confident that its CNS delivery platforms could differentiate it from other gene therapy approaches.
The biggest risk remains that clinical biology may not translate: management repeatedly said it still does not know what level of tau lowering or tau-PET change is needed for meaningful clinical benefit. The SOD1 program setback showed that payload issues can force resets even when the capsid platform is unchanged, and the anti-tau space is still being shaped by external data that could go either way. Investors also have to wait for major readouts, with several key data points not arriving until 2026 or later.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.7%
- Shares Outstanding
- 62.23M
- Float Shares
- 52.11M
of shares held by institutions
144 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 6.77M | ▲ 1.60M |
| Millennium Management LLC | 4.44M | ▲ 1.01M |
| Armistice Capital, LLC | 3.44M | ▼ 64.00K |
| Vanguard Group Inc | 3.27M | ▲ 16.42K |
| Vestal Point Capital, LP | 2.63M | ▼ 377.94K |
| Vanguard Capital Management LLC | 2.35M | 0 |
| Geode Capital Management, LLC | 1.21M | ▼ 117.85K |
| Opaleye Management Inc. | 1.19M | ▲ 35.00K |
| State Street Corp | 1.10M | ▲ 19.71K |
| Two Sigma Investments, LP | 948.52K | ▲ 332.86K |
| Vanguard Portfolio Management LLC | 813.55K | ▲ 3.46K |
| Citadel Advisors LLC | 784.07K | ▲ 419.40K |
Held by 146 ETFs
Biggest fund positions in VYGR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 1, 26 | Carter Todd Alfred | other | 33,000 |
| Nov 1, 26 | Carter Todd Alfred | other | 154,000 |
| Nov 1, 26 | Swartz Robin | other | 318,500 |
| Nov 1, 26 | Swartz Robin | other | 68,250 |
| Jun 9, 26 | SCANGOS GEORGE A | other | 30,000 |
| Jun 9, 26 | MACKEY CATHERINE J | other | 30,000 |
| Jun 9, 26 | Hyman Steven | other | 30,000 |
| Jun 9, 26 | Vitale Nancy | other | 30,000 |
| Jun 9, 26 | Higgins Michael J | other | 30,000 |
| Jun 9, 26 | Onyia Jude | other | 30,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VYGR coverage
Recent articles, reports, and earnings notes.
No research on VYGR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VYGR report →Voyager Therapeutics Eyes Tau Antibody Data and Alzheimer's Gene Therapy Dosing
marketbeat.com · Nov 16
Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Healthcare Conference 2026 Prepared Remarks Transcript
seekingalpha.com · Nov 11
Voyager Therapeutics (VYGR) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 5
Voyager's Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer's Disease to Be Featured in Poster Presentations at CTAD 2026
globenewswire.com · Oct 27
Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And More
seekingalpha.com · Oct 23
Voyager Announces CEO Succession Plan, Appoints Robin Swartz President
globenewswire.com · Oct 21
Voyager Therapeutics (NASDAQ:VYGR) Share Price Breaks Below 50 Day Moving Average – Here’s What Happened
defenseworld.net · Oct 13
Tonix Pharmaceuticals (NASDAQ:TNXP) and Voyager Therapeutics (NASDAQ:VYGR) Critical Review
defenseworld.net · Sep 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.